Medicare Enrolled
Dr. Yuval Raizen, MD
Hematology & Oncology · Houston, TX
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Raizen from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Raizen? Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Raizen
Dr. Yuval Raizen is a hematology & oncology in Houston, TX, with 17 years in practice. Based on federal Medicare data, Dr. Raizen performed 185,531 Medicare services across 2,364 unique beneficiaries.
Between the years covered by Open Payments, Dr. Raizen received a total of $6,344 from 54 pharmaceutical and/or device companies across 317 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Raizen is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 17 years in practice▲ Top 2% volume in TX$ $6,344 industry payments
Medicare Practice Summary
Medicare Utilization ↗185,531
Medicare services
Top 2% in TX for hematology & oncology
2,364
Unique beneficiaries
$12
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~10,914 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron infusion (Feraheme) | 45,390 | $0 | $2 |
| Pembrolizumab injection (Keytruda) | 36,800 | $42 | $220 |
| Darbepoetin injection (Aranesp) for anemia | 30,800 | $2 | $13 |
| Oxaliplatin chemotherapy injection | 30,400 | $0 | $0 |
| Anti-nausea injection (fosaprepitant) | 16,950 | $0 | $1 |
| Contrast dye for imaging (iodine-based) | 6,000 | $0 | $0 |
| Dexamethasone injection (steroid) | 3,740 | $0 | $1 |
| Anti-nausea injection (Aloxi/palonosetron) | 2,480 | $1 | $4 |
| Injection, leucovorin calcium, per 50 mg | 2,130 | $3 | $16 |
| Injection, pegfilgrastim-jmdb (fulphila), biosimilar, 0.5 mg | 1,608 | $93 | $547 |
| Injection, fluorouracil, 500 mg | 1,483 | $2 | $10 |
| Complete blood count (CBC) with differential | 1,386 | $7 | $24 |
| Office visit, established patient (30-39 min) | 1,143 | $91 | $395 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 615 | $22 | $92 |
| Injection, zoledronic acid, 1 mg | 537 | $6 | $38 |
| Administration of chemotherapy into vein, 1 hour or less | 496 | $96 | $415 |
| Injection, potassium chloride, per 2 meq | 420 | $0 | $1 |
| Drug injection, under skin or into muscle | 363 | $11 | $52 |
| Injection of additional new drug or substance into vein | 346 | $11 | $51 |
| Blood test, basic group of blood chemicals (calcium, ionized) | 325 | $13 | $42 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 231 | $48 | $204 |
| Administration of chemotherapy into vein, each additional hour | 177 | $22 | $89 |
| Blood draw (venipuncture) | 147 | $8 | $9 |
| Administration of additional new drug or substance into vein using push technique | 146 | $42 | $176 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 140 | $15 | $63 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 138 | $1,175 | $5,462 |
| Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | 129 | $131 | $525 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 121 | $101 | $435 |
| Unclassified drugs | 120 | $1 | $2 |
| Administration of additional new drug or substance into vein, 1 hour or less | 118 | $51 | $203 |
| Injection, diphenhydramine hcl, up to 50 mg | 116 | $1 | $5 |
| Office visit, established patient, complex (40-54 min) | 75 | $127 | $552 |
| Ct scan of chest with contrast | 60 | $46 | $544 |
| Irrigation of implanted venous access drug delivery device | 58 | $19 | $81 |
| New patient office visit (45-59 min) | 55 | $126 | $512 |
| CT scan of abdomen and pelvis with contrast | 54 | $181 | $1,006 |
| Blood creatinine level | 53 | $5 | $16 |
| New patient office visit, complex (60-74 min) | 52 | $166 | $677 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 34 | $16 | $64 |
| Injection, alteplase recombinant, 1 mg | 32 | $68 | $358 |
| Office visit, established patient (20-29 min) | 29 | $61 | $280 |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 18 | $1 | $5 |
| Declotting of central venous tube | 16 | $26 | $105 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
25.1% high complexity
72.8% medium
2.1% routine
Industry Payment Transparency
Open Payments through 2024 ↗$6,344
Total received (2018-2024)
Avg $906/year across 7 years
Top 39% in TX for hematology & oncology
54
Companies
317
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$6,108 (96.3%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$236 (3.7%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024$1,254
2023$1,376
2022$924
2021$555
2020$850
2019$810
2018$575
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
PFIZER INC.
$767
E.R. Squibb & Sons, L.L.C.
$689
Novartis Pharmaceuticals Corporation
$582
Janssen Biotech, Inc.
$544
Amgen Inc.
$368
Celgene Corporation
$361
GENZYME CORPORATION
$336
Gilead Sciences, Inc.
$294
Myriad Genetic Laboratories, Inc.
$216
Merck Sharp & Dohme Corporation
$142
Exelixis Inc.
$122
Janssen Pharmaceuticals, Inc
$112
Astellas Pharma US Inc
$109
Genentech USA, Inc.
$107
Adaptive Biotechnologies Corporation
$104
AstraZeneca Pharmaceuticals LP
$94
SpringWorks Therapeutics, Inc.
$94
BeiGene USA, Inc.
$85
Incyte Corporation
$78
ABBVIE INC.
$71
Elekta, Inc.
$70
Lilly USA, LLC
$62
Apellis Pharmaceuticals, Inc.
$61
JAZZ PHARMACEUTICALS INC.
$55
Merck Sharp & Dohme LLC
$51
Foundation Medicine, Inc.
$47
PharmaEssentia USA Corporation
$42
SOBI, INC
$41
Puma Biotechnology, Inc.
$39
Stemline Therapeutics Inc.
$37
Fennec Pharmaceuticals, Inc.
$36
Pharmacyclics LLC, an AbbVie Company
$35
TAIHO ONCOLOGY, INC.
$34
Bayer Healthcare Pharmaceuticals Inc.
$31
Regeneron Healthcare Solutions, Inc.
$30
ARRAY BIOPHARMA INC
$30
Pharmacosmos Therapeutics Inc.
$29
Rigel Pharmaceuticals, Inc.
$26
Eisai Inc.
$25
Deciphera Pharmaceuticals Inc.
$25
Secura Bio, Inc.
$24
PUMA BIOTECHNOLOGY, INC.
$24
CTI BioPharma Corp.
$23
Alexion Pharmaceuticals, Inc.
$23
Aurobindo Pharma USA, Inc.
$22
Seagen Inc.
$19
AVEO Pharmaceuticals, Inc.
$19
Boehringer Ingelheim Pharmaceuticals, Inc.
$18
Sysmex Inostics Inc
$18
Agios Pharmaceuticals, Inc.
$17
Blueprint Medicines Corporation
$16
Daiichi Sankyo Inc.
$15
EUSA Pharma (US) LLC
$14
Sirtex Medical Inc
$12
Top 3 companies account for 32.1% of total payments
Associated products mentioned in payments ›
ABECMA · ALIMTA · BESREMI · BOSULIF · BRAFTOVI · BRUKINSA · CABLIVI · CABOMETYX · CALQUENCE · CYRAMZA · Cabometyx · DARZALEX · ELIQUIS · ELITEK · ENDOPREDICT · ENJAYMO · ERLEADA · Empaveli · Enhertu · Erleada · FARYDAK · FOTIVDA · FOUNDATIONONE · Fabhalta · GAVRETO · GILOTRIF · IBRANCE · IMBRUVICA · IMFINZI · INLYTA · JAKAFI · JEVTANA · KEYTRUDA · KISQALI · Kyprolis · LIBTAYO · LONSURF · LUMAKRAS · LUTATHERA · LYNPARZA · Lenvima · Marqibo · Monoferric · NERLYNX · Nerlynx · Nplate · Nubeqa · OGSIVEO · ONUREG · OPDIVO · OPDUALAG · Orserdu · PADCEV · PIQRAY · PROMACTA · Pedmark · Pomalyst · PreciseTumor · Prolia · QINLOCK · REBLOZYL · Rezlidhia · SARCLISA · SCEMBLIX · SIR-Spheres Microspheres · SPRYCEL · SUTENT · SYNAGIS · Sylvant · TAGRISSO · TASIGNA · TECENTRIQ · TIBSOVO · Tecentriq · Trodelvy · ULTOMIRIS · Ultomiris · VENCLEXTA · Vectibix · Venclexta · Versa HD · Vonjo · Vyloy · XALKORI · XARELTO · XGEVA · XTANDI · Xospata · Xtandi · ZEPZELCA · clonoSEQ · myRisk
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (96%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Equivalent to $3 per 100 Medicare services performed
Geographic Context
Hematology & Oncologys within 10 mi
202
Per 100K population
4.2
County median income
$73,104
Nearest hospital
MEMORIAL HERMANN - TEXAS MEDICAL CENTER
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Raizen is a mixed practice specialist, with above-average Medicare volume (top 2% in TX), and low-engagement industry engagement, with 17 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Raizen experienced with iron infusion (feraheme)?
Based on Medicare claims data, Dr. Raizen performed 45,390 iron infusion (feraheme) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Raizen receive payments from pharmaceutical companies?
Yes. Dr. Raizen received a total of $6,344 from 54 companies across 317 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Raizen's costs compare to other hematology & oncologys in Houston?
Dr. Raizen's average Medicare payment per service is $12. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Raizen) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncologys in Houston
Browse hematology & oncologys in Houston ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncologys in TX
Hematology & Oncologys ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncologys in TX
Which TX hematology & oncologys receive the most from drug and device companies.
By company
PFIZER INC. Payments to Doctors
See all physicians who received payments from PFIZER INC..
By company
E.R. Squibb & Sons, L.L.C. Payments to Doctors
See all physicians who received payments from E.R. Squibb & Sons, L.L.C..
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology